Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of "Hold" by Brokerages

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $5.42.

A number of brokerages recently issued reports on OM. BTIG Research initiated coverage on Outset Medical in a research report on Monday, April 8th. They issued a "buy" rating and a $6.00 target price for the company. CL King raised Outset Medical from a "neutral" rating to a "buy" rating and set a $6.00 price target for the company in a report on Friday, April 5th. Finally, Royal Bank of Canada cut shares of Outset Medical from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $14.00 to $6.00 in a research note on Friday, January 12th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of Outset Medical in the third quarter worth approximately $287,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Outset Medical by 36.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 25,323 shares of the company's stock valued at $276,000 after purchasing an additional 6,764 shares during the last quarter. BLB&B Advisors LLC purchased a new stake in shares of Outset Medical during the 3rd quarter valued at $174,000. Eagle Health Investments LP increased its holdings in shares of Outset Medical by 24.5% during the 3rd quarter. Eagle Health Investments LP now owns 1,494,514 shares of the company's stock worth $16,260,000 after buying an additional 294,129 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Outset Medical by 1.7% in the 3rd quarter. Jennison Associates LLC now owns 762,190 shares of the company's stock worth $8,293,000 after buying an additional 12,577 shares during the period.

Outset Medical Stock Down 3.8 %

Shares of OM stock traded down $0.10 during trading on Tuesday, reaching $2.53. The company's stock had a trading volume of 544,254 shares, compared to its average volume of 1,013,805. Outset Medical has a 1-year low of $1.92 and a 1-year high of $24.13. The stock's 50-day moving average price is $2.51 and its 200 day moving average price is $3.78. The company has a market capitalization of $130.81 million, a price-to-earnings ratio of -0.72 and a beta of 1.99. The company has a debt-to-equity ratio of 1.06, a current ratio of 5.26 and a quick ratio of 4.37.

Outset Medical (NASDAQ:OM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.03). The firm had revenue of $30.51 million during the quarter, compared to analyst estimates of $30.40 million. Outset Medical had a negative net margin of 132.54% and a negative return on equity of 102.50%. On average, research analysts anticipate that Outset Medical will post -2.28 EPS for the current year.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.